Austedo Sales: Targeting Tardive Dyskinesia vs. Huntington's Disease
Teva Pharmaceuticals' Austedo (deutetrabenazine) generated $1.2 billion in sales in 2023, with the majority attributable to its indication for tardive dyskinesia (TD) [1]. Huntington's disease (HD) represents a smaller, but significant, portion of Austedo's revenue [1].
How is Austedo Used for Tardive Dyskinesia?
Austedo is prescribed to treat chorea, the involuntary, jerky movements associated with tardive dyskinesia [2]. TD is a neurological disorder often caused by long-term use of antipsychotic medications [2]. Austedo works by reducing the amount of certain neurotransmitters in the brain, which helps to control these movements [3].
What About Austedo for Huntington's Disease?
For Huntington's disease, Austedo is used to manage chorea associated with the condition [4]. Huntington's disease is a progressive, inherited neurodegenerative disorder that affects movement, cognition, and behavior [4]. Like with TD, Austedo helps to alleviate the characteristic involuntary movements [4].
When Might Austedo Patents Expire?
Information regarding the specific patent expiry dates for Austedo is not publicly detailed in this context. However, patent protection is crucial for pharmaceutical manufacturers like Teva to recoup research and development costs [5]. DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceuticals, which can impact market competition [5].
What Are the Potential Risks of Austedo?
Austedo carries a boxed warning regarding the risk of depression and suicidal ideation in patients being treated for TD [3]. Other common side effects can include somnolence, parkinsonism, and akathisia [3]. Patients and healthcare providers carefully weigh these risks against the benefits of symptom control [3].
How Does Austedo Compare to Other Treatments?
For tardive dyskinesia, Austedo is one of the primary pharmacologic treatments available for chorea [2]. Other approaches might involve dose adjustments of the causative antipsychotic or exploring alternative medications [2]. In Huntington's disease, Austedo is also a key treatment option for chorea, alongside supportive care for other symptoms [4].
What Clinical Data Supports Austedo's Efficacy?
Clinical trials have demonstrated Austedo's effectiveness in reducing the severity of chorea in both TD and HD populations [2][4]. Studies like the RIMED-1 and RIMED-2 trials supported its approval for TD, measuring improvements using the Unified Huntington's Disease Rating Scale (UHDRS) chorea-positive subscale [2]. Similarly, trials such as the First-HD study confirmed its efficacy in reducing chorea in Huntington's disease [4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/